| __timestamp | Evotec SE | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17990000 | 10337679 |
| Thursday, January 1, 2015 | 25166000 | 18187286 |
| Friday, January 1, 2016 | 27013000 | 24758063 |
| Sunday, January 1, 2017 | 42383000 | 23666957 |
| Monday, January 1, 2018 | 57012000 | 30099855 |
| Tuesday, January 1, 2019 | 66546000 | 64947625 |
| Wednesday, January 1, 2020 | 77238000 | 186363444 |
| Friday, January 1, 2021 | 105445000 | 272611040 |
| Saturday, January 1, 2022 | 156190000 | 358782000 |
| Sunday, January 1, 2023 | 169610000 | 409864000 |
Cracking the code
In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. From 2014 to 2023, Intra-Cellular Therapies, Inc. and Evotec SE have shown distinct strategies in handling these costs. Intra-Cellular Therapies, Inc. has seen a staggering increase in SG&A expenses, rising by nearly 3,900% over the decade, peaking at approximately $410 million in 2023. In contrast, Evotec SE's expenses grew by about 840%, reaching around $170 million in the same year. This data suggests that while Intra-Cellular Therapies, Inc. is investing heavily in its operations, Evotec SE maintains a more conservative approach. Understanding these trends can provide insights into each company's strategic priorities and financial health, offering a glimpse into their future growth trajectories.
Comparing SG&A Expenses: Merck & Co., Inc. vs Evotec SE Trends and Insights
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Intra-Cellular Therapies, Inc.
Operational Costs Compared: SG&A Analysis of GSK plc and Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. vs Summit Therapeutics Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Ascendis Pharma A/S
Intra-Cellular Therapies, Inc. and TG Therapeutics, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Intra-Cellular Therapies, Inc. vs Verona Pharma plc
Intra-Cellular Therapies, Inc. vs ADMA Biologics, Inc.: SG&A Expense Trends
Intra-Cellular Therapies, Inc. vs Xencor, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Evotec SE
Cost Management Insights: SG&A Expenses for Amphastar Pharmaceuticals, Inc. and Evotec SE
Celldex Therapeutics, Inc. or Evotec SE: Who Manages SG&A Costs Better?